Methylenetetrahydrofolate reductase gene haplotypes affect toxicity during maintenance therapy for childhood acute lymphoblastic leukemia in Japanese patients

Leukemia and Lymphoma

Volumn 55, Issue 5, 2014, Pages 1126-1131

  Tanaka, Yoichi ^a   Manabe, Atsushi ^b   Nakadate, Hisaya ^c   Kondoh, Kensuke ^d   Nakamura, Kozue ^e   Koh, Katsuyoshi ^f   Kikuchi, Akira ^e   Komiyama, Takako ^a  

^a KITASATO UNIVERSITY   (Japan)

^b ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^c NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e TEIKYO UNIVERSITY HOSPITAL   (Japan)

^f SAITAMA CHILDREN'S MEDICAL CENTER   (Japan)

Author keywords

6 mercaptopurine (6 MP); Haplotype; Methotrexate (MTX); Methylenetetrahydrofolate reductase (MTHFR); Toxicity

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); MERCAPTOPURINE; METHOTREXATE; ANTINEOPLASTIC AGENT; INORGANIC PYROPHOSPHATASE; ITPA PROTEIN, HUMAN; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); METHYLTRANSFERASE; THIOPURINE METHYLTRANSFERASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANEMIA; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CONFIDENCE INTERVAL; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; INFECTION; JAPANESE (PEOPLE); LEUKOPENIA; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTE COUNT; ASIAN CONTINENTAL ANCESTRY GROUP; GENETICS; INFANT; JAPAN; MAINTENANCE CHEMOTHERAPY; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PRESCHOOL CHILD; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASIAN CONTINENTAL ANCESTRY GROUP; CHILD; CHILD, PRESCHOOL; FEMALE; HAPLOTYPES; HUMANS; INFANT; JAPAN; MAINTENANCE CHEMOTHERAPY; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); METHYLTRANSFERASES; POLYMORPHISM, SINGLE NUCLEOTIDE; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PYROPHOSPHATASES;

EID: 84894504039     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.825902     Document Type: Article

References (30)

1. Pui CH, Mullighan CG, Evans WE, et al. Pediatric acute lymphoblastic leukemia: Where are we going and how do we get there? Blood 2012; 120: 1165-1174.
2. Relling MV, Hancock ML, Rivera GK, et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 1999; 91: 2001-2008.
3. Dervieux T, Medard Y, Verpillat P, et al. Possible implication of thiopurine S-methyltransferase in occurrence of infectious episodes during maintenance therapy for childhood lymphoblastic leukemia with mercaptopurine. Leukemia 2001; 15: 1706-1712.
4. Dokmanovic L, Urosevic J, Janic D, et al. Analysis of thiopurine S-methyltransferase polymorphism in the population of Serbia and Montenegro and mercaptopurine therapy tolerance in childhood acute lymphoblastic leukemia. Ther Drug Monit 2006; 28: 800-806.
5. Stocco G, Cheok MH, Crews KR, et al. Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 85: 164-172.
6. Desire S, Balasubramanian P, Bajel A, et al. Frequency of TPMT alleles in Indian patients with acute lymphatic leukemia and effect on the dose of 6-mercaptopurine. Med Oncol 2010; 27: 1046-1049.
7. Kapoor G, Sinha R, Naithani R, et al. Thiopurine S-methyltransferase gene polymorphism and 6-mercaptopurine dose intensity in Indian children with acute lymphoblastic leukemia. Leuk Res 2010; 34: 1023-1026.
8. Tanaka Y, Manabe A, Nakadate H, et al. The activity of the inosine triphosphate pyrophosphatase affects toxicity of 6-mercaptopurine during maintenance therapy for acute lymphoblastic leukemia in Japanese children. Leuk Res 2012; 36: 560-564.
9. van Kooten Niekerk PB, Schmiegelow K, Schroeder H. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate. Eur J Haematol 2008; 81: 391-398.
10. D ' Angelo V, Ramaglia M, Iannotta A, et al. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants. Cancer Chemother Pharmacol 2011; 68: 1339-1346.
11. Faganel Kotnik B, Grabnar I, Bohanec Grabar P, et al. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma. Eur J Clin Pharmacol 2011; 67: 993-1006.
12. Karathanasis NV, Stiakaki E, Goulielmos GN, et al. The role of the methylenetetrahydrofolate reductase 677 and 1298 polymorphisms in Cretan children with acute lymphoblastic leukemia. Genet Test Mol Biomarkers 2011; 15: 5-10.
13. El-Khodary NM, El-Haggar SM, Eid MA, et al. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia. Med Oncol 2012; 29: 2053-2062.
14. Haase R, Elsner K, Merkel N, et al. High dose methotrexate treatment in childhood ALL: Pilot study on the impact of the MTHFR 677C-T and 1298A-C polymorphisms on MTX-related toxicity. Klin Padiatr 2012; 224: 156-159.
15. Milek M, Smid A, Tamm R, et al. Post-Translational stabilization of thiopurine S-methyltransferase by S-Adenosyl-L-methionine reveals regulation of TPMT 1 and 3C allozymes. Biochem Pharmacol 2012; 83: 969-976.
16. Costea I, Moghrabi A, Laverdiere C, et al. Folate cycle gene variants and chemotherapy toxicity in pediatric patients with acute lymphoblastic leukemia. Haematologica 2006; 91: 1113-1116.
17. Shimasaki N, Mori T, Torii C, et al. Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2008; 30: 347-352.
18. Karas-Kuzelicki N, Jazbec J, Milek M, et al. Heterozygosity at the TPMT gene locus, augmented by mutated MTHFR gene, predisposes to 6-MP related toxicities in childhood ALL patients. Leukemia 2009; 23: 971-974.
19. Manabe A, Ohara A, Hasegawa D, et al. Significance of the complete clearance of peripheral blasts after 7 days of prednisolone treatment in children with acute lymphoblastic leukemia: The Tokyo Children's Cancer Study Group Study L99-15. Haematologica 2008; 93: 1155-1160.
20. Weisberg I, Tran P, Christensen B, et al. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 1998; 64: 169-172.
21. Nishida A, Kubota T, Yamada Y, et al. Thiopurine S-methyltransferase activity in Japanese subjects: Metabolic activity of 6-mercaptopurine 6-methylation in different TPMT genotypes. Clin Chim Acta 2002; 323: 147-150.
22. De Mattia E, Toff oli G. C 677T and A1298C MTHFR polymorphisms, achallenge for antifolate and fluoropyrimidine-based therapy personalisation. Eur J Cancer 2009; 45: 1333-1351.
23. Dorababu P, Naushad SM, Linga VG, et al. Genetic variants of thiopurine and folate metabolic pathways determine 6-MP-mediated hematological toxicity in childhood ALL. Pharmacogenomics 2012; 13: 1001-1008.
24. Aplenc R, Thompson J, Han P, et al. Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 2005; 65: 2482-2487.
25. Karas Kuzelicki N, Milek M, Jazbec J, et al. 5,10- Methylenetetrahydrofolate reductase (MTHFR) low activity genotypes reduce the risk of relapse-related acute lymphoblastic leukemia (ALL). Leuk Res 2009; 33: 1344-1348.
26. Sepe D M, McWilliams T, Chen J, et al. Germline genetic variation and treatment response on CCG-1891. Pediatr Blood Cancer 2012; 58: 695-700.
27. Krajinovic M, Moghrabi A. Pharmacogenetics of methotrexate. Pharmacogenomics 2004; 5: 819-834.
28. Krajinovic M, Lemieux-Blanchard E, Chiasson S, et al. Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 2004; 4: 66-72.
29. Chiusolo P, Reddiconto G, Farina G, et al. MTHFR polymorphisms ' influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res 2007; 31: 1669-1674.
30. Tantawy AA, El-Bostany EA, Adly AA, et al. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis 2010; 21: 28-34.